{"id":"NCT01626872","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Long-Term Study of MP-214 in Patients With Schizophrenia","officialTitle":"Long-Term Extension Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-09","primaryCompletion":"2016-10","completion":"2016-10","firstPosted":"2012-06-25","resultsPosted":"2021-04-12","lastUpdate":"2021-04-12"},"enrollment":254,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"MP-214 3mg","otherNames":[]},{"type":"DRUG","name":"MP-214 6mg","otherNames":[]},{"type":"DRUG","name":"MP-214 9mg","otherNames":[]},{"type":"DRUG","name":"Risperidone 4mg","otherNames":[]}],"arms":[{"label":"MP-214 3mg","type":"EXPERIMENTAL"},{"label":"MP-214 6mg","type":"EXPERIMENTAL"},{"label":"MP-214 9mg","type":"EXPERIMENTAL"},{"label":"Risperidone 4mg","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","timeFrame":"Up to 60 weeks (Treatment Period (48 weeks) and Follow-up Period (12 weeks))","effectByArm":[{"arm":"MP-214 3mg","deltaMin":67,"sd":null},{"arm":"MP-214 6mg","deltaMin":92,"sd":null},{"arm":"MP-214 9mg","deltaMin":50,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":3,"countries":["Japan","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":81},"commonTop":["Nasopharyngitis","Schizophrenia","Akathisia","Insomnia","Constipation"]}}